- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | ELUTIA INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| ELUTIA Aktie jetzt für 0€ handeln | |||||
| 07.11. | Elutia outlines plan for NXT-41x launch in $1.5B breast reconstruction market following $88M asset sale | 1 | Seeking Alpha | ||
| 06.11. | ELUTIA INC. - 8-K, Current Report | - | SEC Filings | ||
| 23.10. | Elutia Inc.: Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 | 2 | GlobeNewswire (USA) | ||
| 14.10. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.10. | Elutia appoints medical tech veteran Guido Neels to board of directors | 1 | Investing.com | ||
| 10.10. | Elutia beruft Medizintechnik-Veteranen Guido Neels in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 10.10. | Elutia Inc.: Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors | 2 | GlobeNewswire (USA) | ||
| 07.10. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10. | Elutia closes $88M bioenvelope sale to Boston Scientific | 7 | MassDevice | ||
| 01.10. | Elutia Inc.: Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million | 8 | GlobeNewswire (USA) | ||
| 16.09. | Elutia Inc.: Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation | 1 | GlobeNewswire (USA) | ||
| 09.09. | Elutia To Sell EluPro And CanGaroo Bioenvelopes To Boston Scientific | 447 | AFX News | WASHINGTON (dpa-AFX) - Elutia Inc. (ELUT) has entered into a definitive agreement to sell its EluPro and CanGaroo bioenvelopes, designed to protect patients receiving implantable medical devices... ► Artikel lesen | |
| 09.09. | Elutia sells drug-eluting bioenvelope tech to Boston Scientific for $88M | 5 | MassDevice | ||
| 09.09. | ELUTIA INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.09. | Boston Scientific buys Elutia's bioenvelope business for $88 million | 5 | Seeking Alpha | ||
| 09.09. | Boston Scientific übernimmt Biohüllen-Produkte von Elutia für 88 Millionen US-Dollar | 5 | Investing.com Deutsch | ||
| 09.09. | Elutia Inc.: Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million | 346 | GlobeNewswire (Europe) | - Transaction affirms the strength of Elutia's proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction - - Company to provide update at the H.C.... ► Artikel lesen | |
| 15.08. | Elutia targets $20M EluPro revenue run rate and NXT-41 launch in H2 2026 while advancing hospital penetration | 1 | Seeking Alpha | ||
| 14.08. | Elutia Q2 2025 slides: EluPro drives growth amid cash concerns | 2 | Investing.com |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCELLX | 73,02 | -2,59 % | Arcellx: Stifel bekräftigt "Buy"-Rating im Vorfeld der ASH-Konferenz 2025 | ||
| QIAGEN | 41,790 | +1,79 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,57 | +0,56 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| JANUX THERAPEUTICS | 34,700 | +10,11 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 184,03 | -3,83 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| ADMA BIOLOGICS | 19,185 | +4,72 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 26,060 | +4,01 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,700 | +4,48 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,365 | +0,46 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? | ||
| DYNE THERAPEUTICS | 20,820 | -3,92 % | Dyne Therapeutics: Bernstein hebt Kursziel wegen günstigem Risiko-Ertrags-Verhältnis an | ||
| NUVALENT | 109,92 | +0,50 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,690 | +2,98 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So | ||
| ARS PHARMACEUTICALS | 9,305 | +15,73 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) | $32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 42,130 | -1,06 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,80 | +4,41 % | Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results | Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD... ► Artikel lesen |
ELUTIA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,35 % bei einem Aktienkurs von 0,620 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELUTIA INC finden Sie auf Wallstreet Online.